The non-inferiority of piperonyl-butoxide Yorkool® G3 insecticide-treated nets compared to Olyset®Plus measured by Anopheles arabiensis mortality in experimental huts in Tanzania

Olukayode G. Odufuwa,Masudi Suleiman Maasayi,Emmanuel Mbuba,Watson Ntabaliba,Rose Philipo,Safina Ngonyani,Ahmadi Bakari Mpelepele,Isaya Matanila,Hassan Ngonyani,Jason Moore,Yeromin P. Mlacha,Jennifer C. Stevenson,Sarah Jane Moore
DOI: https://doi.org/10.1186/s12936-024-05130-7
2024-10-17
Malaria Journal
Abstract:Non-inferiority trials are recommended by the World Health Organization (WHO) to demonstrate that health products show comparable efficacy to that of existing standard of care. As part of the WHO Global Malaria Programme (GMP) process of assessment of malaria vector control products, a second-in-class insecticide-treated net (ITN) must be shown to be non-inferior to a first-in-class product based on mosquito mortality. The public health impact of the first-in-class pyrethroid-piperonyl butoxide (PBO) ITN, Olyset ® Plus, has been demonstrated in epidemiological trials in areas with insecticide-resistant mosquitoes, but there is a need to determine the efficacy of other pyrethroid-PBO nets to ensure timely market availability of nets in order to increase access to ITNs. The non-inferiority of a deltamethrin-PBO ITN Yorkool ® G3 was evaluated entomologically against Olyset ® Plus in experimental huts in Tanzania, following WHO guidelines for non-inferiority trials.
infectious diseases,tropical medicine,parasitology
What problem does this paper attempt to address?